DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kelley RK, Verslype C, Cohn AL. , et al.
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Ann Oncol 2017;
28 (03) 528-534
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.